Citi analyst Patrick Donnelly raised the firm’s price target on Guardant Health to $50 from $40 and keeps a Buy rating on the shares post the Q2 report. The analyst says the healthy upside in volume is driving numbers higher.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GH:
- Guardant Health raises FY23 revenue view to $545M-$550M from $535M-$545M
- Guardant Health reports Q2 EPS (67c), consensus ($1.18)
- Guardant Health resolves pending litigation with Illumina
- Guardant360 CDx to receive national reimbursement approval from MHLW
- Guardant Health assumed with an Overweight at JPMorgan